CJC-1295 + Ipamorelin
A popular research-peptide stack pairing the GHRH analog CJC-1295 (no-DAC / Mod GRF 1-29) with the selective secretagogue ipamorelin, intended to amplify natural growth-hormone release. No human trials exist on the combination itself.
In plain English
This is a blend, not a single drug: it combines CJC-1295 (no DAC), a GHRH analog, with ipamorelin, a ghrelin-receptor secretagogue. The rationale is that the two act on different receptors and may produce a larger, more natural pulse of growth hormone together than either alone. It is one of the most common stacks in age-management and recovery clinics. Important caveat: there are no published human trials of this specific combination. What evidence exists is for the individual components — and even those have only limited human data. Neither component is FDA-approved, and any combined safety or efficacy claims are extrapolation, not proof.
What it is
A combination of two research peptides: CJC-1295 without DAC (also called Modified GRF 1-29), a short-acting analog of growth-hormone-releasing hormone (GHRH 1-29), and ipamorelin, a selective pentapeptide agonist of the ghrelin/growth-hormone secretagogue receptor (GHS-R). Neither is an approved drug; the pairing is sold and used only as research peptides.
Mechanism (summary)
The two peptides target complementary pathways that converge on growth-hormone release from the pituitary. CJC-1295 (no DAC) mimics GHRH, stimulating the GHRH receptor; ipamorelin mimics ghrelin at the GHS-R and also blunts somatostatin tone. In principle, combining a GHRH analog with a secretagogue produces a synergistic, pulsatile GH release that more closely resembles the body's own rhythm than either agent alone. This mechanistic rationale is plausible from the individual pharmacology but has not been validated for the combination in controlled human studies.
Why people research it
- Pulsatile growth-hormone and IGF-1 elevation for body composition
- Recovery, sleep quality, and general age-management use
- Whether dual-pathway stimulation outperforms a single agent
- Lean-mass support and fat metabolism in research settings
Human evidence
There are no published randomized controlled trials of the CJC-1295 + ipamorelin combination. The supporting human data are limited and pertain to the separate components: a 2006 trial showed CJC-1295 raised GH and IGF-1 in healthy adults, and ipamorelin has early human data (e.g., a phase 2 postoperative-recovery trial). Combining them is a clinical practice extrapolated from this single-agent pharmacology, not something demonstrated in head-to-head or combination trials. Both peptides remain unapproved.
Animal / lab evidence
Ipamorelin was characterized in animal models as the first highly selective GH secretagogue that raises GH without meaningfully increasing cortisol or prolactin. GHRH analogs likewise stimulate GH in animals. There is no significant animal literature on this specific commercial blend; the combination rationale is built from the individual molecules' established preclinical profiles.
Key studies
Each summary explains the design, what was found, and what it doesn't prove.
This trial supports only the CJC-1295 half of the blend: a single injection raised GH and IGF-1 in healthy adults. It says nothing about stacking it with ipamorelin.
This foundational study describes the ipamorelin half of the blend — a clean GH-releaser in animals. It is component evidence, not proof the combination works in people.
One of the only human trials touching ipamorelin — in surgery recovery, not muscle building, and not in combination with CJC-1295.
History
The pairing emerged from the peptide-clinic and bodybuilding communities as a way to stack a GHRH analog with a ghrelin-mimetic secretagogue, marrying CJC-1295 (developed by ConjuChem) with ipamorelin (developed by Novo Nordisk and studied for postoperative ileus). It is marketed as a 'GH stack' despite the absence of combination trials.
PeptidePedia is for educational and informational purposes only. We do not sell peptides, prescribe peptides, provide medical advice, or recommend treatment. Peptides may not be approved for human use except in specific legal prescription or clinical contexts. Always consult a licensed medical professional before making health decisions.
Related peptides
A long-acting GHRH analog studied as a research peptide for sustained growth hormone elevation.
A selective ghrelin receptor agonist studied as a growth hormone secretagogue with minimal effects on cortisol or prolactin.
A 29-amino-acid GHRH analog formerly FDA-approved for childhood growth hormone deficiency.
A long-acting GHRH analog FDA-approved as Egrifta for HIV-associated visceral fat accumulation.